Burning Rock Biotech (BNR) Non-Current Deffered Revenue (2019 - 2021)

Burning Rock Biotech's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at -$40700.8 for Q2 2021.

• In Q2 2021, Non-Current Deffered Revenue fell 210.0% year-over-year to -$40700.8; the TTM figure through Jun 2021 stood at -$40700.8 (down 210.0% YoY), while the FY2020 annual figure was $40000.0, down 71.55% from the prior year.
• Non-Current Deffered Revenue was -$40700.8 for Q2 2021 at Burning Rock Biotech, down from $39684.9 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $140603.8 in Q4 2019 to a low of -$40700.8 in Q2 2021.
• Historically, Non-Current Deffered Revenue has averaged $43117.6 across 3 years, with a median of $39000.0 in 2020.
• The sharpest annual moves came in 2020 and 2021: Non-Current Deffered Revenue slumped 71.78% in 2020, then slumped 210.0% in 2021.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $140603.8 in 2019, then plunged by 71.78% to $39684.9 in 2020, then plunged by 202.56% to -$40700.8 in 2021.
• The last three Non-Current Deffered Revenue figures came in at -$40700.8 (Q2 2021), $39684.9 (Q4 2020), and $39000.0 (Q3 2020), per Business Quant data.